Press Releases | Boehringer Ingelheim US
Press Releases
Search
Partnering Days
Partnering Days
A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
Medical Affairs & Scientific Comms. | Boehringer Ingelheim US
Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.
Introducing Ingelvac Provenza™ | Boehringer Ingelheim US
Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
How to Apply
To apply for the program, please complete one of the following application forms and follow the directions on the application form submission
PAP Resources
PAP Resources
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Grass Roots
Grass Roots
Chronic Kidney Disease
Chronic Kidney Disease
Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US
Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.
Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US
The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.
Pradaxa® (dabigatran etexilate) Medication Guide
Swine
Swine
Heart Diseases
Heart Diseases